<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00369551</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02718</org_study_id>
    <secondary_id>NCI-2012-02718</secondary_id>
    <secondary_id>UCCRC-14576A</secondary_id>
    <secondary_id>CDR0000491998</secondary_id>
    <secondary_id>NCI-7213</secondary_id>
    <secondary_id>14576A</secondary_id>
    <secondary_id>7213</secondary_id>
    <secondary_id>P30CA014599</secondary_id>
    <secondary_id>N01CM62201</secondary_id>
    <nct_id>NCT00369551</nct_id>
  </id_info>
  <brief_title>Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Safety and Feasibility Study of Bevacizumab With Paclitaxel, Carboplatin and Chest Radiotherapy in Patients With Locally Advanced Non-Small Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase I trial studies how well giving bevacizumab together with paclitaxel, carboplatin,&#xD;
      and radiation therapy to the chest works in treating patients with locally advanced non-small&#xD;
      cell lung cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in&#xD;
      different ways. Some block the ability of tumor cells to grow and spread. Others find tumor&#xD;
      cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop&#xD;
      the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy,&#xD;
      such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. Radiation therapy uses&#xD;
      high-energy x-rays to kill tumor cells. Giving bevacizumab together with paclitaxel,&#xD;
      carboplatin, and radiation therapy may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Assess the feasibility of administering bevacizumab, paclitaxel, carboplatin, and chest&#xD;
      radiotherapy in patients with locally advanced non-small cell lung cancer.&#xD;
&#xD;
      II. Characterize the toxicity of this treatment regimen. III. Assess the clinical response to&#xD;
      this treatment regimen. IV. Correlate circulating levels of angiopoietin-2 and vascular&#xD;
      endothelial growth factor receptor-2 with clinical response to this treatment regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.Induction therapy.&#xD;
&#xD;
      Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30-60 minutes on days 1,&#xD;
      8, 15, 22, 29, 36, and 43 and bevacizumab IV over 30-90 minutes on days 1, 15, 29, and 43.&#xD;
      Patients also undergo chest radiotherapy 5 days a week for 7 weeks beginning on day 1.&#xD;
&#xD;
      Consolidation therapy: Beginning 4-5 weeks after completion chemoradiotherapy, patients&#xD;
      receive paclitaxel IV over 1 hour followed by carboplatin IV over 1 hour followed by&#xD;
      bevacizumab IV over 30 minutes. Treatment repeats every 21 days for 3 courses in the absence&#xD;
      of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After study completion, patients are followed periodically for 36 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2006</start_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and feasibility</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In-field toxicity, defined as bleeding or perforation of the tracheobronchial or gastrointestinal structures within the radiation field</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of levels of angiopoietin-2 and vascular endothelial growth factor receptor-2 with clinical response</measure>
    <time_frame>Up to 36 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Adenocarcinoma of the Lung</condition>
  <condition>Bronchoalveolar Cell Lung Cancer</condition>
  <condition>Large Cell Lung Cancer</condition>
  <condition>Stage II Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIA Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (paclitaxel, carboplatin, bevacizumab, radiation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive paclitaxel IV over 1 hour and carboplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, 36, and 43 and bevacizumab IV over 30-90 minutes on days 1, 15, 29, and 43. Patients also undergo chest radiotherapy 5 days a week for 7 weeks beginning on day 1.&#xD;
Consolidation therapy: Beginning 4-5 weeks after completion chemoradiotherapy, patients receive paclitaxel IV over 1 hour followed by carboplatin IV over 1 hour followed by bevacizumab IV over 30 minutes. Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
    <description>Undergo 3-dimensional conformal radiation therapy</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, bevacizumab, radiation)</arm_group_label>
    <other_name>3D conformal radiation therapy</other_name>
    <other_name>3D-CRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, bevacizumab, radiation)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>Asotax</other_name>
    <other_name>TAX</other_name>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, bevacizumab, radiation)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, bevacizumab, radiation)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, bevacizumab, radiation)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung carcinoma (NSCLC)&#xD;
             meeting the following criteria:&#xD;
&#xD;
               -  The following subtypes are eligible:&#xD;
&#xD;
                    -  Adenocarcinoma (including bronchoalveolar)&#xD;
&#xD;
                    -  Large cell carcinoma (including giant and clear cell carcinomas)&#xD;
&#xD;
                    -  Poorly differentiated carcinoma&#xD;
&#xD;
               -  No squamous cell histology&#xD;
&#xD;
               -  Unresectable stage II-III disease&#xD;
&#xD;
               -  Tumor must not invade the trachea or major arterial or venous structures&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Measurable disease defined as ? 1 lesion that can be accurately measured in ? 1&#xD;
                  dimension as ? 20 mm with conventional techniques or as ? 10 mm with spiral CT&#xD;
                  scan&#xD;
&#xD;
          -  No evidence of CNS disease, including primary brain tumor or brain metastases&#xD;
&#xD;
          -  ECOG performance status (PS) 0-1 or Karnofsky PS 60-100%&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Granulocyte count ? 1,500/mm³&#xD;
&#xD;
          -  Platelet count ? 100,000/mm³&#xD;
&#xD;
          -  Bilirubin &lt; 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST &lt; 2.5 times ULN&#xD;
&#xD;
          -  Creatinine normalOR creatinine clearance ? 60 mL/min&#xD;
&#xD;
          -  FEV_1 ? 1.0 liters&#xD;
&#xD;
          -  24-hour urine protein &lt; 1,000 mg (for patients with urine protein:creatinine ratio [by&#xD;
             urine analysis] &gt; 1.0)&#xD;
&#xD;
          -  No hemoptysis within the past 12 months (defined as bright red blood in sputum of &gt; 1&#xD;
             teaspoon)&#xD;
&#xD;
          -  No known hypersensitivity to Chinese hamster ovary cell products or other recombinant&#xD;
             human antibodies&#xD;
&#xD;
          -  No history of allergic reactions attributed to carboplatin or taxane&#xD;
&#xD;
          -  No serious or nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within&#xD;
             the past 28 days&#xD;
&#xD;
          -  No significant traumatic injury within the past 14 days&#xD;
&#xD;
          -  No clinically significant cardiovascular disease, including any of the following:&#xD;
&#xD;
               -  Cerebrovascular accident within the past 6 months&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Myocardial infarction or unstable angina within the past 6 months&#xD;
&#xD;
               -  New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
               -  Serious cardiac arrhythmia requiring medication&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Clinically significant peripheral vascular disease&#xD;
&#xD;
          -  No known bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  No active bleeding or pathological condition that carries a high risk of bleeding&#xD;
             (e.g., tumor involving major vessels or known varices)&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, the following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Psychiatric illness or social situations that would limit study compliance&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ? 6 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No prior epidermal growth factor receptor-targeted therapy&#xD;
&#xD;
          -  No prior vascular endothelial growth factor-targeted therapy&#xD;
&#xD;
          -  No prior chest radiotherapy&#xD;
&#xD;
          -  No major surgery or open biopsy within the past 14 days&#xD;
&#xD;
          -  No concurrent treatment with full-dose anticoagulation&#xD;
&#xD;
               -  Low-dose anticoagulants (e.g., warfarin) to maintain patency of central venous&#xD;
                  catheter allowed provided all of the following criteria are met:&#xD;
&#xD;
                    -  Daily dose of warfarin &lt; 1 mg&#xD;
&#xD;
                    -  INR &lt; 1.5&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent major surgical procedures&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
&#xD;
          -  No concurrent chronic treatment with aspirin (&gt; 325 mg daily) or nonsteroidal&#xD;
             anti-inflammatory agents&#xD;
&#xD;
          -  No dexamethasone as an antiemetic during chemoradiotherapy&#xD;
&#xD;
          -  No colony-stimulating factors during chemoradiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Everett Vokes</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>August 24, 2006</study_first_submitted>
  <study_first_submitted_qc>August 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2006</study_first_posted>
  <last_update_submitted>March 5, 2014</last_update_submitted>
  <last_update_submitted_qc>March 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
    <mesh_term>Adenocarcinoma, Bronchiolo-Alveolar</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

